Venlafaxine Alternatives Compared
Venlafaxine | Xyrem | Sodium oxybate |
|
---|
Venlafaxine | Xyrem (sodium oxybate) | Sodium oxybate |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Venlafaxine is an antidepressant that may also be used for mood disorders and off-label for some other conditions such as hot flashes. It may cause a discontinuation syndrome if abruptly stopped... View more |
Prescription only
Xyrem is a Schedule III controlled substance when prescribed to treat narcolepsy; however, there is a high risk of abuse associated with it and people who misuse it or sell it to other people are... View more |
Prescription only
Prescribed for Idiopathic Hypersomnia, Narcolepsy, Fibromyalgia, Cataplexy. sodium oxybate may also be used for purposes not listed in this medication guide. |
Related suggestions Cataplexy
|
|||||||||||||||||||||||
More about Venlafaxine | More about Xyrem (sodium oxybate) | More about Sodium oxybate | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Venlafaxine has an average rating of 6.4 out of 10 from a total of 2748 ratings on Drugs.com. 54% of reviewers reported a positive effect, while 28% reported a negative effect. |
Xyrem has an average rating of 7.7 out of 10 from a total of 107 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 14% reported a negative effect. |
Sodium oxybate has an average rating of 7.8 out of 10 from a total of 121 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 14% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: venlafaxine side effects in more detail. |
See also: Xyrem side effects in more detail. |
See also: sodium oxybate side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
Lower cost generic |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all venlafaxine prices |
View all Xyrem prices |
View all sodium oxybate prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Effexor, Effexor XR | Other sodium oxybate brands include: Lumryz | Lumryz, Xyrem | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
4 hours |
1 hour |
1 hour |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Moderate abuse potential
Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
Moderate abuse potential
Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 684 drugs are known to interact with venlafaxine:
|
A total of 342 drugs are known to interact with Xyrem:
|
A total of 342 drugs are known to interact with sodium oxybate:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
December 28, 1993 |
July 17, 2002 |
N/A |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
|
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.